What is the 13F Pro Quality Score for CRL?

13F Pro ranks CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CRL's current score at https://13fpro.ai/research/CRL (free sign-up required for the full ranking).

Which hedge funds own the most CRL stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of CRL include BlackRock,, FMR, VANGUARD CAPITAL MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/CRL as soon as new 13F filings post.

Where does 13F Pro source CRL data?

All CHARLES RIVER LABORATORIES INTERNATIONAL, INC. fundamentals and ownership data come directly from SEC EDGAR. CHARLES RIVER LABORATORIES INTERNATIONAL, INC. files with the SEC under CIK 1100682. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CRL in?

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CRL research updated on 13F Pro?

CRL's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.(CRL)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 1100682 CRL stock profile & AI dashboard →

13F Pro Quality Score

47.1/100

Rank #1,611 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

28.2/100

Profitability

32.6/100

Balance Sheet

49.0/100

Earnings Quality

6.9/100

Free Cash Flow

65.8/100

Institutional Flow

80.9/100

Revenue Scale

74.6/100

Dilution Risk

43.2/100

CRL Stock Analysis & AI Quality Score

AI stock analysis and institutional research for CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CRL at 47.1/100 on a 32-signal composite quality model, placing it at rank #1,611 of 2,879 stocks — the bottom half of the AI-ranked universe. CRL scores in the top quartile across institutional flow (80.9). Areas of concern include earnings quality (6.9) and revenue growth (28.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 43.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), CHARLES RIVER LABORATORIES INTERNATIONAL, INC. reports quarterly revenue of $995.8M, net income of $-14.8M, free cash flow of $-14.8M. Top institutional holders of CRL by reported 13-F value include BlackRock,, FMR, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. CRL trades on the NYSE exchange and files with the SEC under CIK 1100682. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CRL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CHARLES RIVER LABORATORIES INTERNATIONAL, INC. directly from SEC EDGAR. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.'s 13F Pro composite quality score has ranged between 43 and 71 since 2021, currently 47.1 — a declining long-term trajectory across 30 quarterly and live scoring snapshots.

✦

Fun facts about CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Quirks, history, and lore behind CRL — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · mid-cap · listed on the NYSE · headquartered in Massachusetts.
2
The Numbers
Pulls in roughly $4 billion in annual revenue and serves over 100 of the top 100 global pharmaceutical and biotech companies — essentially the whole industry is a client.
3
The History
Founded in 1947 by a veterinarian named Henry Foster, it started by breeding germ-free laboratory rats in a converted Boston stable, and somehow turned that into a multibillion-dollar empire.
4
The Secret
It doesn't make drugs — it makes drug development possible, running preclinical research, safety testing, and contract research services so pharma giants don't have to do their own dirty work.
5
The Lore
The company's Sprague-Dawley rat and other proprietary research animal models have been used in so many studies they're practically co-authors on modern medicine.
6
The Giveaway
Its name evokes a New England waterway and a famous colonial-era scientist — and its three-letter ticker is the abbreviation for that same river. Drugs don't get approved without passing through its labs first.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$995.8M

Net Income

Q1 2026

$-14.8M

Free Cash Flow

Q1 2026

$-14.8M

ROIC

Q1 2026

2.1%

D/E Ratio

Q1 2026

0.91

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-0.9% YoY

$4.02BFY 2025

FY21 $3.54BFY23 $4.13BFY24 $4.05BFY25 $4.02B

Net Income

-750.1% YoY

$-144.3MFY 2025

FY21 $391.0MFY23 $474.6MFY24 $22.2MFY25 $-144.3M

Operating Income

-88.9% YoY

$25.2MFY 2025

FY21 $589.9MFY23 $617.3MFY24 $227.3MFY25 $25.2M

EPS (Diluted)

-1555.0% YoY

$-2.91FY 2025

FY21 $7.60FY23 $9.22FY24 $0.20FY25 $-2.91

Total Assets

-5.2% YoY

$7.14BFY 2025

FY21 $7.02BFY23 $8.20BFY24 $7.53BFY25 $7.14B

Total Debt

-4.6% YoY

$2.14BFY 2025

FY21 $2.67BFY23 $2.66BFY24 $2.24BFY25 $2.14B

Op. Cash Flow

+0.4% YoY

$737.6MFY 2025

FY21 $760.8MFY23 $683.9MFY24 $734.6MFY25 $737.6M

Metric	FY 2025	FY 2024	FY 2023	FY 2021	FY 2020	FY 2019
Revenue	$4.02B -0.9%	$4.05B -1.9%	$4.13B +16.6%	$3.54B +21.1%	$2.92B +11.5%	$2.62B
Net Income	$-144.3M -750.1%	$22.2M -95.3%	$474.6M +21.4%	$391.0M +7.3%	$364.3M +44.6%	$252.0M
Operating Income	$25.2M -88.9%	$227.3M -63.2%	$617.3M +4.6%	$589.9M +36.3%	$432.7M +23.2%	$351.2M
EPS (Diluted)	$-2.91 -1555.0%	$0.20 -97.8%	$9.22 +21.3%	$7.60 +5.6%	$7.20 +42.0%	$5.07
Total Assets	$7.14B -5.2%	$7.53B -8.1%	$8.20B +16.7%	$7.02B +27.9%	$5.49B +17.0%	$4.69B
Total Debt	$2.14B -4.6%	$2.24B -15.5%	$2.66B -0.4%	$2.67B +31.5%	$2.03B +5.4%	$1.92B
Operating Cash Flow	$737.6M +0.4%	$734.6M +7.4%	$683.9M -10.1%	$760.8M +39.2%	$546.6M +13.6%	$480.9M

AI Insight: CRL Financial Trends

CRL's Q1 2026 operating income recovered to $120M but a $537M debt surge and near-zero operating cash flow of $41M signal acute near-term stress.

• Revenue has been range-bound between $984M and $1,032M across all eight quarters, showing no meaningful top-line growth.

• Operating income improved from -$283M in Q4 2025 to $120M in Q1 2026, recovering toward Q2 2024 levels of $152M.

• Total debt jumped from $2,140M in Q4 2025 to $2,678M in Q1 2026, the highest level in the entire period, while equity fell to $2,941M.

• Operating cash flow collapsed to $41M in Q1 2026, the weakest reading in the dataset, down from $214M in Q3 2025.

⚠ Back-to-back Q4 net losses (-$214M in Q4 2024, -$277M in Q4 2025) suggest recurring year-end impairments or restructuring charges worth monitoring.

⚠ Equity has eroded from $3,782M in Q3 2024 to $2,941M in Q1 2026 — a $841M decline — raising leverage concerns.

⚠ Whether Q1 2026's $41M operating cash flow normalizes or reflects a structural FCF deterioration is the key inflection to track next quarter.

AI Insight: CRL Ratio Trends

Recurring Q4 impairment charges are masking an otherwise recovering operating business, but TTM profitability has collapsed to near-zero.

• Operating margin recovered from -16.7% in Q4 2024 to 12.0% in Q1 2026, signaling underlying business stabilization outside year-end charges.

• Q4 impairments are deepening: operating margin fell to -28.5% in Q4 2025 versus -16.7% in Q4 2024, suggesting larger write-downs year-over-year.

• TTM net profit margin stands at -4.6% and ROIC at just 1.2%, dragged down by back-to-back Q4 losses overwhelming interim quarter gains.

• D/E ratio rose to 0.91 in Q1 2026, the highest level in the observed period, reversing prior deleveraging progress.

⚠ Whether Q4 charges recur in magnitude — two consecutive Q4 blow-ups (-16.7%, -28.5% OpMargin) suggest a structural, not one-off, pattern.

⚠ D/E jumping to 0.91 in Q1 2026 from 0.64 in Q3 2025 warrants scrutiny; rising leverage alongside negative TTM earnings is a stress signal.

⚠ Q1 2026 ROIC of 8.5% on an annualized basis looks encouraging, but negative NPM (-1.5%) in the same quarter signals below-the-line drags to monitor.

Get alerted when CRL's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for CHARLES RIVER LABORATORIES INTERNATIONAL, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CRL

BlackRock, Inc.
$665.7M3,859,100 sh
FMR LLC
$596.2M3,456,244 sh
VANGUARD CAPITAL MANAGEMENT LLC
$552.4M3,202,204 sh
Invesco Ltd.
$413.5M2,397,252 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$395.8M2,294,670 sh
HARRIS ASSOCIATES L P
$371.4M2,153,296 sh
Allspring Global Investments Holdings, LLC
$348.6M1,993,316 sh
STATE STREET CORP
$323.2M1,873,618 sh
DIMENSIONAL FUND ADVISORS LP
$285.0M1,652,484 sh
WELLINGTON MANAGEMENT GROUP LLP
$281.1M1,629,401 sh

Fund	Value	Shares
BlackRock, Inc.	$665.7M	3,859,100
FMR LLC	$596.2M	3,456,244
VANGUARD CAPITAL MANAGEMENT LLC	$552.4M	3,202,204
Invesco Ltd.	$413.5M	2,397,252
VANGUARD PORTFOLIO MANAGEMENT LLC	$395.8M	2,294,670
HARRIS ASSOCIATES L P	$371.4M	2,153,296
Allspring Global Investments Holdings, LLC	$348.6M	1,993,316
STATE STREET CORP	$323.2M	1,873,618
DIMENSIONAL FUND ADVISORS LP	$285.0M	1,652,484
WELLINGTON MANAGEMENT GROUP LLP	$281.1M	1,629,401

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CRL on your watchlist

Track score changes the day CHARLES RIVER LABORATORIES INTERNATIONAL, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CRL a good stock to buy?

13F Pro's AI-powered analysis of CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CRL are available on the CRL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own CRL?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CRL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of CHARLES RIVER LABORATORIES INTERNATIONAL, INC.'s investment landscape.